Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

[img]
Preview
Text
108468.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer‐related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic disease. Hence, preventing metastatic disease in these patients would be of significant benefit. Using principal component analysis (PCA), we identified a LOX/hypoxia signature associated with poor patient survival in resectable patients. We found that LOX expression is upregulated in metastatic tumors from Pdx1‐Cre KrasG12D/+ Trp53R172H/+ (KPC) mice and that inhibition of LOX in these mice suppressed metastasis. Mechanistically, LOX inhibition suppressed both migration and invasion of KPC cells. LOX inhibition also synergized with gemcitabine to kill tumors and significantly prolonged tumor‐free survival in KPC mice with early‐stage tumors. This was associated with stromal alterations, including increased vasculature and decreased fibrillar collagen, and increased infiltration of macrophages and neutrophils into tumors. Therefore, LOX inhibition is able to reverse many of the features that make PDAC inherently refractory to conventional therapies and targeting LOX could improve outcome in surgically resectable disease.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jamieson, Dr Nigel and Bailey, Dr Peter and Shanks, Dr Emma and Oien, Dr Karin and Anderson, Professor Kurt and Biankin, Professor Andrew and Timpson, Dr Paul and Carter, Mr Christopher and McGhee, Dr Ewan and McGarry, Ms Lynn and Evans, Professor Thomas and Steele, Dr Colin and Morton, Dr Jennifer and Chang, Dr David and Karim, Ms Saadia and Sansom, Professor Owen
Authors: Miller, B. W., Morton, J. P., Pinese, M., Saturno, G., Jamieson, N. B., McGhee, E., Timpson, P., Leach, J., McGarry, L., Shanks, E., Bailey, P., Chang, D., Oien, K., Karim, S., Au, A., Steele, C., Carter, C. R., McKay, C., Anderson, K., Evans, T. R. J., Marais, R., Springer, C., Biankin, A., Erler, J. T., and Sansom, O. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:EMBO Molecular Medicine
Publisher:EMBO Press
ISSN:1757-4676
ISSN (Online):1757-4684
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in EMBO Molecular Medicine
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record